Skip to contentP
Protagonist Therapeutics, Inc
P
PTGXProtagonist Therapeutics, Inc Q2 2026 · 10-Q
Revenue$213.48M$213.48M+3,749.2% vs Q2 2025 Net Income$162.85M$162.85MN/M vs Q2 2025 EPS Diluted$2.29$2.29N/M vs Q2 2025 Operating Income$158,766,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protagonist Therapeutics, Inc · CIK 1377121 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$218,884,000N/M Margins · derivedOperating margin74.4%+832.4 pt vs Q2 2025
Net margin76.3%+703.2 pt vs Q2 2025
ended Jun 30, 2026 · filed Aug 5, 2026 · 36 d after period end